Pathophysiology and Clinical Manifestations of Left-Sided Heart Failure

Initial Myocardial Injury and Etiology

Coronary artery disease causes approximately two-thirds of cases of left ventricular systolic dysfunction, making it the predominant underlying etiology, according to the American College of Cardiology 1, 2
The remaining one-third of cases have nonischemic causes, including hypertension, valvular disease, myocardial toxins, myocarditis, or idiopathic dilated cardiomyopathy, as reported by the American College of Cardiology 1, 2

The principal manifestation of disease progression is ventricular remodeling, which represents homeostatic attempts to decrease wall stress through increases in wall thickness, as stated by the American College of Cardiology 1, 2
This remodeling process results in geometric changes where the left ventricle dilates, hypertrophies, and becomes more spherical rather than maintaining its normal elliptical shape, according to the American College of Cardiology 1, 2

Left ventricular dysfunction creates a self-perpetuating cycle: decreased cardiac output leads to impaired tissue oxygen delivery and neurohormonal activation, which results in systemic venous congestion, as described by the American Society of Anesthesiologists 3, 4
Systemic venous congestion decreases venous return to the right heart by causing systemic interstitial fluid accumulation, while simultaneously increasing left-sided filling pressures that cause pulmonary fluid accumulation, according to the American Society of Anesthesiologists 3, 4

The cardinal manifestations are dyspnea and fatigue, which limit exercise tolerance, and fluid retention, which leads to pulmonary and peripheral edema, as reported by the American College of Cardiology 1, 2
A critical and poorly understood discordance exists between ejection fraction severity and functional impairment—patients with very low ejection fractions may be asymptomatic while those with preserved systolic function may have severe disability, according to the American College of Cardiology 1, 2

Left-sided heart failure is a progressive disease with established risk factors, asymptomatic phases, and symptomatic phases—analogous to the oncology model of disease progression, as stated by the American College of Cardiology 1, 2
The disease can be characterized by four stages of evolution, recognizing that treatments at each stage can reduce morbidity and mortality, according to the American College of Cardiology 1, 2

The occurrence of organ dysfunction during acute decompensation is associated with poor outcomes and requires aggressive management, as described by the American Society of Anesthesiologists 3, 4

The American College of Cardiology states that the Law of Laplace, which explains how wall stress is directly proportional to intracavitary pressure and internal ventricular diameter, and inversely proportional to wall thickness, is critical in understanding heart failure 5, 6
The Law of Laplace is represented by the equation: Wall Stress = (Pressure × Radius) / Wall Thickness, providing fundamental insight into cardiac mechanics 7

The American College of Cardiology guidelines emphasize that changes in chamber size and structure increase the hemodynamic stresses on the walls of the failing heart, leading to a vicious cycle of progressive deterioration 5, 6
Chamber dilatation increases radius, which directly increases wall stress despite any compensatory hypertrophy, according to the Law of Laplace 5, 6
Increased wall stress depresses mechanical performance of the failing heart 5, 6
The spherical shape of the ventricle creates regionally variable stress patterns that worsen mitral regurgitation 5, 6

The American College of Cardiology emphasizes that cardiac remodeling generally precedes the development of symptoms, continues after the appearance of symptoms, and contributes substantially to worsening of symptoms despite treatment 5, 8
Understanding the Law of Laplace guides heart failure treatment strategies, including reducing wall stress through multiple mechanisms such as ACE inhibitors, ARBs, diuretics, and beta-blockers 5, 9
The American College of Cardiology recommends considering chamber dimensions and geometry, not just ejection fraction, when evaluating heart failure patients 5, 6

Reducing wall stress through pressure reduction (afterload reduction), volume reduction (diuresis), and prevention of progressive dilatation (neurohormonal blockade) are key treatment strategies 5, 9
ACE inhibitors and ARBs reduce pressure, thereby decreasing wall stress 5, 9
Diuretics reduce preload and ventricular volume, lowering wall stress 5, 9
Beta-blockers allow reverse remodeling by reducing pressure and potentially decreasing chamber size over time 5, 9

The right ventricle is particularly sensitive to afterload changes because of the Law of Laplace, with minor increases in afterload causing large decreases in stroke volume 7
Neurohormonal activation amplifies the problem by causing sodium retention and peripheral vasoconstriction, stimulating myocardial fibrosis, and directly altering ventricular architecture 5, 8

The European Society of Cardiology guidelines state that coronary heart disease is the predominant cause of heart failure in younger age groups, where heart failure is more common in men, occurring in earlier decades 10, 11
Ischemic heart disease represents the principal etiology of heart failure in the Western world and well-developed countries 12

In younger populations, coronary heart disease causes heart failure predominantly in men due to earlier onset of ischemic disease 10, 11
In elderly populations, the prevalence of heart failure becomes equal between sexes, though coronary disease remains the leading cause 10, 11
The overall prevalence of heart failure is increasing due to population aging and improved survival after coronary events 10, 11

The success in postponing coronary events through effective primary and secondary prevention has contributed to the overall increase in heart failure prevalence 10, 11